Advisory Committee Recommendations, Voting Outcomes, New Appointments, and Stock Price Movements - Research Report on Merck, Bristol-Myers Squibb, Boston Scientific, WellCare, and PAREXEL

NEW YORK, December 17, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY), Boston Scientific Corporation (NYSE: BSX), WellCare Health Plans, Inc. (NYSE: WCG) and PAREXEL International Corporation (NASDAQ: PRXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Merck & Co., Inc. Research Report

On December 12, 2013, Merck Co., Inc. (Merck) issued a statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). According to Merck, the proposed trade name for the Company's investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis, with or without conjunctivitis, in appropriate adult and pediatric patients who are candidates for immunotherapy. Dr. Sean Curtis, Vice President, Respiratory and Immunology, Merck Research Laboratories, said, "We are pleased with the positive discussion of GRASTEK at today's advisory committee meeting. We believe GRASTEK has the potential to be an important new oral therapeutic option for allergy specialists and their patients who continue to suffer with Timothy grass pollen induced allergic rhinitis, and we look forward to continuing to work with the FDA as the agency completes its review of our biologics license application for GRASTEK." Merck expects the FDA's review of GRASTEK to be completed in H1 2014. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

Bristol-Myers Squibb Co. Research Report

On December 12, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) and AstraZeneca announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13-1 that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Bristol-Myers Squibb added that the advisory committee voted 10-4 that the data provided sufficient evidence that dapagliflozin, relative to comparators has an acceptable cardiovascular risk profile. The Company also stated that the FDA is not bound by the Advisory Committee's recommendation but takes its advice into consideration when reviewing the application for an investigational agent. Also, Bristol-Myers Squibb informed that the Prescription Drug User Fee Act (PDUFA) goal date for dapagliflozin is January 11, 2014. The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

Boston Scientific Corporation Research Report

On December 11, 2013, Boston Scientific Corporation (Boston Scientific) announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, with 13 voting 'Yes' and 1 voting 'No,' that the benefits of the Company's WATCHMAN Left Atrial Appendage Closure device outweighs the risks. The Company was also asked if there is reasonable assurance that the device is safe, the Panel voted Yes: 13, No: 1. Further, on the question of reasonable assurance of efficacy to the Company, the Panel voted Yes: 13, No: 1. Commenting on the vote results, Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific, said, "We are pleased with the outcome of today's Panel, which represents an important milestone toward making this innovative technology available to patients with AF at higher risk for stroke who need an alternative to long-term warfarin therapy. We appreciate the opportunity to present our comprehensive data supporting the WATCHMAN technology and look forward to continuing discussions with the FDA regarding the Panel's comments." The Company expects a decision from the FDA in H1 2014. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5640_BSX

WellCare Health Plans, Inc. Research Report

On December 12, 2013, WellCare Health Plans, Inc. (WellCare) announced that it has named John J. Burke state President of New York, effective September 13, 2014, when he began serving in the role on an interim basis. The Company informed that Burke is responsible for WellCare's Medicaid and Medicare Advantage operations in New York and for growth initiatives across the state. Commenting on his appointment, Dave Reynolds, WellCare's Region President for Connecticut, Illinois, Montana, New Jersey, New York, and Ohio, said, "John has solid experience and expertise in government-funded health care programs, and will continue to be an asset to WellCare as we focus on working with our state customer, providers and community organizations in bringing New Yorkers quality, coordinated care in a cost-effective manner." The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/be48_WCG

PAREXEL International Corporation Research Report

On December 12, 2013, PAREXEL International Corporation's (PAREXEL) stock rose slightly by 0.07%, ending the day at $41.28. Over the previous three trading sessions, shares of PAREXEL declined 4.42% compared to the Nasdaq Composite which also declined 1.73% during the same period. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:    

http://www.analystscorner.com/r/full_research_report/067b_PRXL

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner